Slingshot members are tracking this event:

Theravance Biopharma to Present New Data Highlighting Potent in vitro Activity of VIBATIV (telavancin) Against Difficult-to-Treat, Clinical Pathogens, Including MRSA, at ASM Microbe 2016 Conference

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
TBPH Community voting in process

Additional Information

Additional Relevant Details Theravance Biopharma today announced that data from new studies of VIBATIV (telavancin) will be presented at the American Society of Microbiology (ASM) Microbe 2016 Conference, being held in Boston, MA, on June 16-20, 2016. New data on the potent in vitro activity of VIBATIV against isolates from a range of difficult-to-treat infections, including methicillin-resistant Staphylococcus aureus (MRSA), will be highlighted in several poster presentations at the conference.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 20, 2016
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Mrsa, Staphylococcus Aureus, Vancomycin, Daptomycin